A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)

Trial Profile

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Capecitabine; Eribulin; Gemcitabine; Vinorelbine
  • Indications Breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-119
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 20 Apr 2017 Planned End Date changed from 1 Nov 2017 to 30 May 2019.
    • 20 Apr 2017 Planned primary completion date changed from 1 May 2017 to 1 Aug 2018.
    • 02 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top